Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia

Journal of Neurochemistry

Volumn 88, Issue 6, 2004, Pages 1449-1454

  Mount, Howard T J ^a,b   Martel, Jean Claude ^c   Fluit, Paul ^a   Wu, Yingji ^a   Gallo Hendrikx, Eleanor ^a   Cosi, Cristina ^c   Marien, Marc R ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

ATM; ATP; Dopamine NAD; PARP; Rotarod

Indexed keywords

ANTIPARKINSON AGENT; ATM PROTEIN; BRAIN MONOAMINE; DOPAMINE; DOPAMINE TRANSPORTER; LEVODOPA; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA TELANGIECTASIA; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DNA DAMAGE; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; HIGH ENERGY PHOSPHATE; IMMUNOREACTIVITY; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION;

ANIMALIA; PARKINSONIA;

EID: 1642351894     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02278.x     Document Type: Article

References (32)

1. Agamanolis D. P. and Greenstein J. I. (1979) Ataxia-telangiectasia: report of a case with Lewy bodies and vascular abnormalities within cerebral tissue. J. Neuropathol. Exp. Neurol. 38, 475-489.
2. Barlow C., Hirotsune S., Paylor R. et al. (1996) Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159-171.
3. Barlow C., Dennery P. A., Shigenaga M. K., Smith M. A., Morrow J. D., Roberts L. J. 2nd, Wynshaw-Boris A. and Levine R. L. (1999) Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc. Natl. Acad. Sci. USA 96, 9915-9919.
4. Barlow C., Ribault-Barassin C., Zwingman T. A. et al. (2000) ATM is a cytoplasmic protein in mouse brain required to prevent lysosomal accumulation. Proc. Natl Acad. Sci. USA 97, 871-876.
5. Borghesani P. R., Alt F. W., Bottaro, A., Davidson L., Aksoy S., Rathbun G. A., Roberts T. M., Swat W., Segal R. A. and Gu Y. (2000) Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proc. Natl Acad. Sci. USA 97, 3336-3341.
6. Chan P., DeLanney L. E., Irwin I., Langston J. W. and DiMonte D. (1991) Rapid ATP loss caused by 1-methyl-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57, 348-351.
7. Chiesa N., Barlow C., Wynshaw-Boris A., Strata P. and Tempia F. (2000) Atm-deficient Purkinje cells show age-dependent defects in calcium spike bursts and calcium currents. Neuroscience 96, 575-583.
8. Cosi C. and Marien M. (1998) Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly (ADP-ribose) polymerase inhibitor, benzamide. Brain Res. 809, 58-67.
9. Cosi C. and Marien M. (1999) Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism: decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. Ann. NY Acad. Sci. 890, 227-239.
10. Cosi C., Chopin P. and Marien M. (1996) Benzamide, an inhibitor of poly (ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouse. Brain Res. 735, 343-348.
11. Dantzer F., Ménissier de Murcia J., Barlow C., Wynshaw-Boris A. and de Murcia G. (1999) Poly (ADP-ribose) polymerase activity is not affected in ataxia telangiectasia cells and knockout mice. Carcinogenesis 20, 177-180.
12. Edwards M. J. and Taylor A. M. R. (1980) Unusual levels of (ADP-ribose)n and DNA synthesis in ataxia telangiectasia cells following γ-ray irradiation. Nature 287, 745-747.
13. Eilam R., Peter Y., Elson A., Rotman G., Shiloh Y., Groner Y. and Segal M. (1998) Selective loss of dopaminergic nigro-striatal neurons in brains of Atm-deficient mice. Proc. Natl Acad. Sci. USA 95, 12653-12656.
14. Eilam R., Peter Y., Groner Y. and Segal M. (2003) Late degeneration of nigro-striatal neurons in Atm-/- mice. Neuroscience 121, 83-98.
15. Elson A., Wang Y., Daugherty C. J., Morton C. C., Zhou F., Campos-Torres J. and Leder P. (1996) Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl Acad. Sci. USA 93, 13084-13089.
16. Jones D. P. (1981) Determination of pyridine dinucleotides in cell extracts by high-performance liquid chromatography. J. Chromatogr. 225, 446-449.
17. Kamsler A., Daily D., Hochman A., Stern N., Shiloh Y., Rotman G. and Barzilai A. (2001) Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res. 61, 1849-1854.
18. 123I]iodobenzamide binding. Mov. Disord. 9, 455-459.
19. Lalonde R., Joyal C. C. and Botez M. I. (1994) Exploration and motor coordination in dystonia musculorum mutant mice. Physiol. Behav. 56, 277-280.
20. Mandir A. S., Przedborski S., Jackson-Lewis V., Wang Z. Q., Simbulan-Rosenthal C. M., Smulson M. E., Hoffman B. E., Guastella D. B., Dawson V. L. and Dawson T. M. (1999) Poly (ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl Acad. Sci. USA 96, 5774-5779.
21. Mount H. T. J., Wu Y., Fluit P., Bi Q., Crawford T. O. and Mandir A. S. (2002) Parkinsonian features of ataxia-telangiectasia and of the Atm-deficient mouse, in: Parkinson's Disease (Ronken, E., Turski, L., van Scharrenburg, G., eds), pp. 182-193. IOS Publishers, Amsterdam.
22. Pecker I., Avraham K. B., Gilbert D. J. et al. (1996) Identification and chromosomal localization of Atm, the mouse homolog of the ataxia-telangiectasia gene. Genomics 35, 39-45.
23. Quick K. L. and Dugan L. L. (2001) Superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia. Ann. Neurol. 49, 627-635.
24. Savitsky K., Bar-Shira A., Gilad S. et al. (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749-1753.
25. Sedgwick R. P. and Boder E. (1991) Ataxia-Telangiectasia, in: Handbook of Clinical Neurology (de Jong, J. M. B. V., ed.), pp. 347-423, Vol. 16. (60) Hereditary Neuropathies and Spinocerebellar Atrophies Elsevier, Amsterdam.
26. Shiloh Y. (2001) ATM (ataxia telangiectasia mutated): expanding roles in the DNA damage response and cellular homeostasis. Biochem. Soc. Trans. 6, 661-666.
27. Soares H. D., Morgan J. I. and McKinnon P. J. (1998) Atm expression patterns suggest a contribution from the peripheral nervous system to the phenotype of ataxia-telangiectasia. Neuroscience 86, 1045-1054.
28. Sotelo C. and Guenet J. L. (1988) Pathological changes in the CNS of dystonia musculorum mutant mouse: an animal model for human spinocerebellar ataxia. Neuroscience 27, 403-424.
29. Stern N., Hochman A., Zemach N., Hammel I., Shiloh Y., Rotman G. and Barzilai A. (2002) Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of Atm-deficient mice. J. Biol. Chem. 277, 602-608.
30. Wood P. L. and Altar C. A. (1988) Dopamine release in vivo from nigrostriatal, mesolimbic and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol. Rev. 40, 163-187.
31. Xu Y., Ashley T., Brainerd E. E., Bronson R. T., Meyn M. S. and Baltimore D. (1996) Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10, 2411-2422.
32. Zwelling L. A., Kerrigan D. and Mattern M. R. (1983) Ataxia-telangiectasia cells are not uniformly deficient in poly (ADP-ribose) synthesis following X-irradiation. Mutat. Res. 120, 69-78.